Phosphodiesterase 4 inhibitors for the treatment of asthma
- 1 September 1997
- journal article
- Published by Taylor & Francis in Expert Opinion on Therapeutic Patents
- Vol. 7 (9) , 989-1003
- https://doi.org/10.1517/13543776.7.9.989
Abstract
No abstract availableKeywords
This publication has 38 references indexed in Scilit:
- Design and Synthesis of Conformationally Constrained Analogs of 4-(3-Butoxy-4-methoxybenzyl)imidazolidin-2-one (Ro 20-1724) as Potent Inhibitors of cAMP-Specific PhosphodiesteraseJournal of Medicinal Chemistry, 1995
- Expression and regulation of human and rat phosphodiesterase type IV isogenesFEBS Letters, 1994
- Theophylline in the management of asthma: time for reappraisal?European Respiratory Journal, 1994
- Immunochemical characterization of the distinct monocyte cyclic AMP-phosphodiesterase from patients with atopic dermatitisJournal of Allergy and Clinical Immunology, 1993
- T cells and eosinophils in the pathogenesis of asthmaImmunology Today, 1992
- Synergistic Effects of Interleukin 4 and Interferon-Gamma on Monocyte Phosphodiesterase ActivityJournal of Investigative Dermatology, 1992
- The Isoenzyme Selectivity of AH 21–132 as an Inhibitor of Cyclic Nucleotide Phosphodiesterase ActivityJournal of Enzyme Inhibition, 1991
- Primary sequence of cyclic nucleotide phosphodiesterase isozymes and the design of selective inhibitorsTrends in Pharmacological Sciences, 1990
- Inhibition of exercise-induced asthma by an orally absorbed mast cell stabilizer (M & B 22,948)Respiratory Medicine, 1983
- The granulocyte response to the phosphodiesterase inhibitor RO 20-1724 in asthmaJournal of Allergy and Clinical Immunology, 1981